We have located links that may give you full text access.
Journal Article
Randomized Controlled Trial
Risperidone adjunctive therapy duration in the maintenance treatment of bipolar I disorder: A post hoc analysis.
Journal of Affective Disorders 2019 March 2
BACKGROUND: Risperidone, an atypical antipsychotic medication, is recommended as a first line treatment for acute mania in patients with bipolar disorder I (BD I). It is unknown if continuing treatment with risperidone adjunct to lithium or valproate after remission of the manic episode offers additional benefit in prevention of mood episode relapse.
METHODS: A post-hoc subgroup analysis was conducted using data from a 52-week, double-blind, placebo controlled trial involving 93 patients treated with oral risperidone adjunct to mood stabilizer, randomized to arms discontinuing risperidone at entry ("0-week arm"), 24 weeks after entry ("24-week arm") or continuing risperidone ("52-week arm"). Time to any episode, manic episode, and depressive episode was compared between arms using Cox regression models.
RESULTS: Time to any mood episode was longer in the 24-week arm versus the 0-week arm (HR: 0.57, 95% CI: 0.31-1.05, P = 0.07) and shorter in the 52-week arm versus 24-week arm (HR: 1.85, 95% CI: 1.00-3.41, P = 0.05), though these results were not significant. Time to relapse into manic episode was significantly longer in the 24-week arm versus 0-week arm (HR: 0.14, 95% CI: 0.03, 0.65, P = 0.01). No other significant differences were observed between arms.
LIMITATIONS: The sample size was modest, as the original dataset was powered to study optimal duration for two atypical antipsychotics.
CONCLUSIONS: Adjunctive risperidone treatment was observed to reduce the risk of manic episodes during the first 24 weeks, but not after 24 weeks. Treatment did not appear to reduce the risk of depressive episodes.
METHODS: A post-hoc subgroup analysis was conducted using data from a 52-week, double-blind, placebo controlled trial involving 93 patients treated with oral risperidone adjunct to mood stabilizer, randomized to arms discontinuing risperidone at entry ("0-week arm"), 24 weeks after entry ("24-week arm") or continuing risperidone ("52-week arm"). Time to any episode, manic episode, and depressive episode was compared between arms using Cox regression models.
RESULTS: Time to any mood episode was longer in the 24-week arm versus the 0-week arm (HR: 0.57, 95% CI: 0.31-1.05, P = 0.07) and shorter in the 52-week arm versus 24-week arm (HR: 1.85, 95% CI: 1.00-3.41, P = 0.05), though these results were not significant. Time to relapse into manic episode was significantly longer in the 24-week arm versus 0-week arm (HR: 0.14, 95% CI: 0.03, 0.65, P = 0.01). No other significant differences were observed between arms.
LIMITATIONS: The sample size was modest, as the original dataset was powered to study optimal duration for two atypical antipsychotics.
CONCLUSIONS: Adjunctive risperidone treatment was observed to reduce the risk of manic episodes during the first 24 weeks, but not after 24 weeks. Treatment did not appear to reduce the risk of depressive episodes.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app